```
=> s l7
SAMPLE SEARCH INITIATED 11:18:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1807 TO ITERATE

100.0% PROCESSED     1807 ITERATIONS                                 22 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        33590 TO     38690
PROJECTED ANSWERS:             159 TO       721

L8           22 SEA SSS SAM L7

=> s l7 sss full
FULL SEARCH INITIATED 11:18:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    34174 TO ITERATE

100.0% PROCESSED    34174 ITERATIONS                                382 ANSWERS
SEARCH TIME: 00.00.01

L9          382 SEA SSS FUL L7

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    178.82     370.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -1.60

FILE 'CAPLUS' ENTERED AT 11:18:32 ON 07 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Jan 2008  VOL 148 ISS 2
FILE LAST UPDATED: 6 Jan 2008  (20080106/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l9
```

L10 3 L9

=> d l10 1-3 bib abs fhitstr

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1350732 CAPLUS
DN 144:81208
TI (2-Benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethylphenyl))methanone for the treatment of schizophrenia
IN Lesage, Anne Simone Josephine; Ashton, David; Janssens, Frans Eduard
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005123081	A2	20051229	WO 2005-EP52887	20050621
	WO 2005123081	A3	20060316		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2004-102885	A	20040622		

GI



I

AB This invention discloses the use of (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethylphenyl)methanone and its derivs. having neurokinin antagonistic activity, in particular a combined NK1/NK2/NK3 antagonistic

activity to modulate the activity of dopaminergic pathways in the brain, as a medicine for the prophylactic and/or therapeutic treatment of schizophrenia. Compds. of the invention include I and the pharmaceutically acceptable acid or base addition salts thereof, the stereochem. isomeric forms thereof, the N-oxide form thereof, and prodrugs thereof. Compound preparation is described.

IT 717923-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(piperazinyl derivative neurokinin antagonist for treatment of schizophrenia)

RN 717923-73-4 CAPLUS

CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[(3S)-1-[[(3S)-tetrahydro-3-furanyl]carbonyl]-3-pyrrolidinyl]-1-piperazinyl]-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:550948 CAPLUS

DN 141:106496

TI Preparation of substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists

IN Janssens, Frans Eduard; Sommen, Francois Maria; De Boeck, Benoit Christian Albert Ghislain; Leenaerts, Joseph Elisabeth

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056799	A2	20040708	WO 2003-EP51041	20031217
	WO 2004056799	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2508657	A1	20040708	CA 2003-2508657	20031217
AU	2003302488	A1	20040714	AU 2003-302488	20031217
EP	1581518	A2	20051005	EP 2003-810849	20031217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR	2003017658	A	20051206	BR 2003-17658	20031217
CN	1726207	A	20060125	CN 2003-80106356	20031217
JP	2006514027	T	20060427	JP 2004-561504	20031217
IN	2005DN02725	A	20070105	IN 2005-DN2725	20050620
US	2006040950	A1	20060223	US 2005-540447	20050622
MX	2005PA06887	A	20050816	MX 2005-PA6887	20050623
NO	2005003569	A	20050915	NO 2005-3569	20050721
PRAI WO	2002-EP14831	A	20021223		
WO	2003-EP51041	W	20031217		

OS MARPAT 141:106496

GI



I



II

AB Title compds. I [Q = O or NR3; X = covalent bond, -O-, -S-, or -NR3; R1 independently = Ar1, Ar1-alkyl, and di(Ar1)-alkyl; R2 = Ar2, Ar2-alkyl, di(Ar2)-alkyl Het1, Het1-alkyl; R3 independently = H or alkyl; Y = covalent bond, -CO-, -SO2-, >C:CHR or >C:NR, wherein R = H, CN or NO2; M independently = covalent bond, (un)substituted-alkyl, -(un)saturated carbocycle; L = H, alkyloxy, Ar3oxy, alkylamine, etc.; Ar1 = (un)substituted phenyl; Ar2 = (un)substituted naphthalenyl or Ph with substituent(s) selected from halo, alkyl, CN, aminocarbonyl, and alkyloxy; Ar3 = (un)substituted naphthalenyl or Ph with substituent(s) selected from halo, alkyl, CN, amino, alkyloxy, OH, pyridinyl, etc.; Het1 = monocyclic heterocyclic radical selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, etc.; m = 1 or 2 provided that if m = 2, then n = 1; n = 0-2; p = 1-2; q = 0-1] and their pharmaceutically acceptable salts having

neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compns. comprising them and their use as a medicine, in particular for the treatment of schizophrenia, anxiety, depression, emesis and IBS are disclosed. Thus, e.g., II was prepared by reaction of (2R-trans) 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(1-piperazinyl)piperidine (preparation given) and 1-(phenylmethyl)-3-pyrrolidinone. The receptor binding values (pIC50) for the h-NK1 ranges for all compds. according to the invention between 10 and 6. In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P and Neurokinin B by blocking the NK1, NK2 and NK3 receptors, the compds. according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of tachykinin-mediated conditions, such as, for instance CNS disorders, in particular schizoaffective disorders, depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions ; inflammation ; allergic disorders ; emesis ; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders ; vasospastic diseases ; fibrosing and collagen diseases ; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.

IT 717923-54-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(stereoselective preparation of piperidinylpyrrolidinylpiperazines with tachykinin antagonist activity)

RN 717923-54-1 CAPLUS

CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[1-(phenylmethyl)-3-pyrrolidinyl]-1-piperazinyl]-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:142666 CAPLUS
DN 136:200479
TI Preparation of proline derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors and use thereof as drugs
IN Kitajima, Hiroshi; Sakashita, Hiroshi; Akahoshi, Fumihiko; Hayashi, Yoshiharu
PA Welfide Corporation, Japan
SO PCT Int. Appl., 340 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014271	A1	20020221	WO 2001-JP6906	20010810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2418656	A1	20020221	CA 2001-2418656	20010810
	AU 200177754	A	20020225	AU 2001-77754	20010810
	EP 1308439	A1	20030507	EP 2001-955660	20010810
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013146	A	20030624	BR 2001-13146	20010810
	HU 2003000746	A2	20031028	HU 2003-746	20010810
	NZ 524618	A	20040827	NZ 2001-524618	20010810
	NO 2003000619	A	20030226	NO 2003-619	20030207
	US 2004106655	A1	20040603	US 2003-344255	20030210
	US 7074794	B2	20060711		
	US 2005245538	A1	20051103	US 2005-142523	20050602
	US 7060722	B2	20060613		
	US 2006173056	A1	20060803	US 2006-351118	20060210
PRAI	JP 2000-243217	A	20000810		
	JP 2000-400296	A	20001228		
	JP 2000-24217	A	20000810		
	WO 2001-JP6906	W	20010810		
	US 2003-344255	A3	20030210		
	US 2005-142523	A3	20050602		

OS MARPAT 136:200479
GI



I

AB The title compds. [I; X = NR1R2, NR3COR4, NR5COR4, NR5CH2CH2NR6R7, NR8SO2R9, OR10, O2CR11; wherein R1, R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or they are linked to each other to form a heterocyclyl containing 1 or 2 N atoms or O which may be a spiro ring and is optionally fused to an (un)substituted aromatic ring; R3, R4 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl; R5, R6, R7 = H, alkyl, acyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, or which is optionally fused to an (un)substituted aromatic ring; R8, R9, R10, R11 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] or pharmacol. acceptable salts thereof are prepared These compds. are useful for the treatment of DPP-IV related diseases such as diabetes, obesity, HIV infection, cancer metastasis, skin diseases, prostatic hypertrophy (prostatomegaly), pericementitis, or autoimmune diseases. Thus, a solution of 0.924 g (S)-1-[(2S,4S)-4-amino-1-tert-butoxycarbonyl-2-pyrrolidinylcarbonyl]-2-cyanopyrrolidine (preparation given), 1.7 mL diisopropylethylamine, and 0.78 g 2-chloro-4-fluorobenzonitrile in 10 mL N-methyl-2-pyrrolidone were stirred at 80° for 4 h to give 0.94 g (S)-1-[(2S,4S)-1-tert-butoxycarbonyl-4-(3-chloro-4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-2-cyanopyrrolidine which (0.93 g) was treated with HCl/EtOAc at room temperature for 15 h to give (S)-1-[(2S,4S)-4-(3-chloro-4-cyanophenyl)amino-2-pyrrolidinylcarbonyl]-2-cyanopyrrolidine hydrochloride (II). II showed IC50 of 0.13 and 0.15 nM against human blood plasma DPP-IV and rat blood plasma DPP-IV, resp.

IT 401563-02-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline derivs. as dipeptidyl peptidase IV (DPP-IV) inhibitors for treating DPP-IV related diseases)

RN 401563-02-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[(3S,5S)-5-(3-thiazolidinylcarbonyl)-3-pyrrolidinyl]-1-piperazinyl]-, ethyl ester, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 4 HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l10 3 hitstr

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
IT 401563-02-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline derivs. as dipeptidyl peptidase IV (DPP-IV) inhibitors for treating DPP-IV related diseases)
RN 401563-02-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[(3S,5S)-5-(3-thiazolidinylcarbonyl)-3-pyrrolidinyl]-1-piperazinyl]-, ethyl ester, tetrahydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●4 HCl

IT 401566-59-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of proline derivs. as dipeptidyl peptidase IV (DPP-IV) inhibitors for treating DPP-IV related diseases)
RN 401566-59-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[(3S,5S)-1-[(1,1-dimethylethoxy)carbonyl]-5-(3-thiazolidinylcarbonyl)-3-pyrrolidinyl]-1-piperazinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



=> file caold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 22.25 392.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -2.40 -4.00

FILE 'CAOLD' ENTERED AT 11:22:28 ON 07 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 19
L11 0 L9

=> file chemcats
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.46 393.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -4.00

FILE 'CHEMCATS' ENTERED AT 11:22:38 ON 07 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE LAST UPDATED 22 DECEMBER 2007 (20071222/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPB, HELP SPC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTB, HELP CTC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not

liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 17 million records. See HELP CONTENT and NEWS FILE for details.

=> s l9
L12 0 L9

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.94	394.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:22:45 ON 07 JAN 2008